4P Pharma, Translating Science to Medicine for Patients
Established in 2014, 4P-Pharma is a clinical stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly. Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down ...
News and events - 4P Pharma
Lille & Paris, September 10th, 2024 – 4P-Pharma, a clinical-stage startup based in Lille that develops disease-modifying therapies for untreated serious diseases, is delighted to welcome Marina Vasiliou, Christian Bechon, and Alain Sainsot as independent and non-executive members to its Board of Directors.
Pipeline - 4P Pharma
Advancing scientific knowledges for untreated serious diseases. 4P-Pharma pipeline covers an extensive spectrum of therapeutic areas, encompassing chronic and autoimmune diseases, respiratory and infectious diseases, preventive therapies, and ophthalmological conditions.
Mar 3, 2022 · 4P-Pharma is a clinical stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases. Driven by a vision to pair disease biology of unmet pathologies with drug mechanism of action, the key differentiation of 4P is the dual leverage of in-house R&D capabilities combined with single product
4P-Pharma and Oncocross sign a research collaboration agreement
Nov 4, 2021 · 4P-Pharma and Oncocross, a Korea-based AI biotech, signed a research collaboration agreement at the Institut Pasteur de Lille on October 25th, 2021. The two companies will join their expertise to bring an innovative therapeutic agent to the patients affected by Systemic Scleroderma, a rare autoimmune disease affecting the skin and internal ...
4P-Pharma Announces Total Capital of €15 Million Successfully …
Lille & Paris, 29th April 2024 – 4P-Pharma, a Lille-based clinical-stage biotechnology company and startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.
4P-Pharma, a recognized actor in the ADHD drug pipeline …
Jun 12, 2018 · 4P-Pharma is a recognized actor in the ADHD pipeline drug development. Stimulant abuse and addiction is surging and is becoming a major global health problem. Recently, the CDC released worrisome data on psychostimulants-related overdose death, with a 33,3% increase from 2015-2016*.
4P-Pharma Reveals Its Brand New Identity
Apr 23, 2024 · 4P-Pharma Reveals Its Brand New Identity. This new identity represents a significant milestone in our company’s journey, from a biotech start-up to a clinical-stage biotech dedicated to developing curative therapies for untreated serious diseases.
Discover 4P-Pharma’s clinical vision
Dec 14, 2022 · This video focuses on our clinical vision, aiming to rapidly deliver effective, regenerated, first-in-class therapies for untreated serious diseases with high unmet medical needs. 4P-Pharma has developed a proprietary development engine to address the main pain points of traditional drug development: time, costs, and predictability to deliver ...
4P-Pharma at CHINA Bio 2023
Sep 13, 2023 · 4P-Pharma at CHINA Bio 2023 We are pleased to announce our company’s participation at CHINA Bio 2023, from September 20 – 21, 2023, in Shanghai, China. Our Chairwoman, Revital Rattenbach, and our CEO, Didier Landais, and Francis Berenbaum, CEO/CMO of our subsidiary, 4Moving Biotech, will attend this event.